Robin Swartz
Fortune : 460 939 $ au 31/10/2026
Fortune : 460 939 $ au 31/10/2026
Mr. Robin Swartz is a President at Voyager Therapeutics, Inc. Mr. Swartz was previously employed as a Vice President-Product Services by Genzyme Therapeutics Ltd. and a Vice President-Patient & Product Services by Genzyme Corp.
He also served on the board at Sanofi-Aventis, Inc. He received his undergraduate degree from Kenyon College.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/11/2026 | 267 988 ( 0,43% ) | 460 939 $ | 31/10/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | President | 20/10/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/06/2020 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Kenyon College
Kenyon College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national